Pharminent

Eli Lilly licenses Adimab antibody discovery and optimization tech

Adimab, LLC is transferring its proprietary antibody discovery and optimization platform to Lilly research sites in San Diego and New York. http://www.outsourcing-pharma.com/Preclinical-Research/Eli-Lilly-licenses-Adimab-antibody-discovery-and-optimization-tech

Filed under: R&D

Sanofi to Acquire Protein Sciences

NewsAcquisition adds recombinant-based influenza vaccine to Sanofi Pasteur’s portfolio.Contributed Author: SanofiTopics: Pharma Mergers & Acquistions https://www.dddmag.com/news/2017/07/sanofi-acquire-protein-sciences

Filed under: Company

Perspectives: More Transparent Pricing System Would Help Untangle Confusion Around High Costs

Read recent commentaries about drug-cost issues. http://khn.org/morning-breakout/perspectives-more-transparent-pricing-system-would-help-untangle-confusion-around-high-costs/

Filed under: Pricing

Trovagene Announces Agreement with Novogene for NextCollect™ in China

SAN DIEGO, July 12, 2017 /PRNewswire/ — Trovagene, Inc. (NASDAQ: TROV), today announced that they have entered into an agreement with Novogene Co. Ltd., a leading global provider of genomic services and solutions with cutting edge next-generation sequencing (NGS) and the largest sequ… http://www.prnewswire.com/news-releases/trovagene-announces-agreement-with-novogene-for-nextcollect-in-china-300486641.html

Filed under: Emerging Markets

Alnylam Buckles Down On A Belt Of Rare Diseases

https://seekingalpha.com/article/4087017-alnylam-buckles-belt-rare-diseases

Filed under: Company

Regulation of orphan drugs within the EU

https://www.europeanpharmaceuticalreview.com/article/62846/3-17-gerstberger/

Filed under: General

AstraZeneca at Cannes: Healthcare delivery’s speeding away from pharma’s marketing model

Can smartphones upend commerce in biopharma? AstraZeneca thinks they might, which is why the U.K.-based drug giant teamed up with Babylon Health in an artificial intelligence pilot project that’s more healthcare than pharma. http://www.fiercepharma.com/marketing/az-at-cannes-healthcare-delivery-speeding-away-from-pharma-model

Filed under: Marketing

Op-Ed: Why single-payer health-care could be closer than you think

How chaos surrounding the GOP’s health-care plan could bring the U.S. closer to single-payer, says Proteus Duxbury. http://www.cnbc.com/2017/06/26/single-payer-health-care-is-closer-than-you-think-commentary.html

Filed under: Payer

EU tests limits of drug pricing freedom in landmark probe

BRUSSELS/LONDON (Reuters) – The first ever EU antitrust probe into excessive drug pricing is taking the European pharmaceuticals industry into uncharted territory, unnerving some companies and lawyers worried about the reach of market intervention.

http://www.reuters.com/article/us-pharmaceuticals-eu-pricing-analysis-idUSKBN19H1IY

Filed under: Pricing

Pfizer To Lose Exclusivity Of Key Brands

https://seekingalpha.com/article/4082947-pfizer-lose-exclusivity-key-brands

Filed under: Company

J&J Innovation Reveals New Collaborations in NASH, Diabetes, and Rheumatoid Arthritis

NewsThese new deals will also help advance cutting-edge technologies, including 3-D printing to create customized health solutions.Contributed Author: J&J InnovationTopics: Biotech https://www.dddmag.com/news/2017/06/j-j-innovation-reveals-new-collaborations-nash-diabetes-and-rheumatoid-arthritis

Filed under: Company

Parexel, Sanofi explore use of wearables in clinical trial

Six years after Pfizer’s landmark REMOTE trial, Parexel and Sanofi are teaming up in a pilot study to revisit the idea of using wearables in clinical trials. http://www.fiercebiotech.com/cro/parexel-sanofi-explore-use-wearables-clinical-trial

Filed under: R&D

CVS Point-Of-Sale Rebate Program Adopted By ‘Several’ Payers

Manufacturer rebates can be used to reduce patient cost sharing at point of sale under the PBM’s program. https://pink.pharmamedtechbi.com/articles/2017/06/15/cvs-pointofsale-rebate-program-adopted-by-several-payers

Filed under: Payer

Sanofi to invest further in biologics

PARIS (Reuters) – Sanofi announced plans to invest 600 million euros ($673 million) annually over the next two to three years in the field of biologics production, an area of strong growth potential.

http://www.reuters.com/article/us-sanofi-biologics-idUSKBN1951IV

Filed under: Company

Continuous Manufacturing: Novartis’ experiment in the future of drug production

Continuous manufacturing has long been touted as the future of drug production. Pharmafile approached Novartis for more details about its successes in the area, and the challenges, of developed the new process.
Why did Novartis decide to take the step to experiment in continuous manufacturing processes? 
read more http://www.pharmafile.com/news/514335/continuous-manufacturing-novartis-experiment-future-drug-production

Filed under: Company

China FDA changes will speed up approval process, says CRO

Proposed changes to drug, medical device and clinical testing regulations provide stimulus for conducting trials in China, says CRO George Clinical. http://www.outsourcing-pharma.com/Clinical-Development/China-FDA-changes-will-speed-up-approval-process-says-CRO

Filed under: Emerging Markets

Industry Pulse: R&D spending in charts

Biopharmas are always on the hunt for ever-elusive innovations, but some are better at allocating investment than others. Here are five charts showing how the industry spends on R&D.  http://www.biopharmadive.com/news/industry-pulse-biopharma-research-development-spending/443506/

Filed under: R&D

AstraZeneca offloads more non-core assets

The British drugmaker has worked to trim its portfolio, selling off older drugs to help offset revenue declines from key products. http://www.biopharmadive.com/news/astrazeneca-offloads-more-non-core-assets/443315/

Filed under: Company

What marketers need to know about tax reform, off-label promotion, pricing

The ad-tax deduction is likely once again on the table. http://www.mmm-online.com/legalregulatory/what-marketers-need-to-know-about-tax-reform-off-label-promotion-pricing/article/662241/

Filed under: Marketing

India’s drugmakers need more time to meet international standards: industry group

MUMBAI (Reuters) – India’s big drugmakers will need at least five more years to improve their manufacturing standards and data reliability to a level demanded by international regulators, said a senior industry official.

http://www.reuters.com/article/us-india-pharmaceuticals-regulation-idUSKCN18D1CU

Filed under: Emerging Markets

Categories